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There is a growing appreciation of the influence of both
the tumour microenvironment and the dynamic nature of
the cellular micro-community in determining tumour pro-
gression and therapeutic resistance. Changes in cell hetero-
geneity, resulting from time-varying changes in the
microenvironment, present complex challenges for cancer
therapy. For example, the tumour micro-community com-
prises multiple levels of cellular interactions overlaid with
pervading influences such as variation in the levels of oxy-
genation. Molecular targeting combined with agents that
target the microenvironment offer novel approaches. The
presentation focused on two examples supported by cyto-
metric techniques. First, dissecting the influences of cellular
interactions on tumour progression-related cell behavior.
An in vitro, non-adherent small cell lung cancer (SCLC)
cell model system enabled the engineering of cellular
micro-communities. SCLC cells show surface expression of
a potential drug target, polysialylated neural cell adhesion
molecule (NCAM; NCAM1 or CD56). The extensive addi-
tion of polysialic acid (polySia) to NCAM in SCLC
decreases membrane apposition, cell adhesion and enables
cell migration. Cytometric studies reveal heterogeneity in
the expression of polySia in SCLC cell populations that can
be related to proliferation potential both in vitro and in
vivo. In constructed 3-D micro-communities, polySia
expression was driven in non-expressing variants by the
presence of over-expressing subpopulations. This suggests
that a degree of homeostasis operates with implications for
polySia-NCAM-targeted therapies. The second example
addressed the targeting of hypoxia for therapeutic advan-
tage using a novel hypoxia activated prodrug (HAP) tech-
nology. Hypoxia in tumour regions, arising from loss of
vascularity, generates drug resistant phenotypes. Targeting
hypoxic tumour cells using HAPs has been previously
attempted using a diverse group of chemicals based mainly
on structures with alkylating functionality. Crucially most
of these agents are reduced in single electron steps by
a number of enzymes including cytochrome P450 reduc-
tase. This produces prodrug conversion to species that
bind covalently to DNA. Critically, the cytotoxins generated
do not persist such that targeted cells upon re-oxygenation
may contribute to tumour regrowth. We have developed
the concept of a unidirectional hypoxia activated prodrug
(uHAP), building upon experience with di-N-oxides of ter-
tiary amine anthraquinones, to develop the novel agent
OCT1002. The uHAP represents a distinct class of HAP,
reduced to a cytotoxic species through an irreversible
two-step process, each involving a two-electron reduction.
The bioactive reduction products inhibit DNA processing
and topoisomerase II activity, selectively causing cancer cell
death. The presentation explored the application of cyto-
metric methods to reveal the mechanisms of action of
OCT1002 and to provide an insight into the targeting of
hypoxic regions of prostate and pancreatic cancers. The
above examples highlight the importance of cell-based
approaches in the development of therapeutic strategies
that address changing patterns of target presentation in dif-
ferent cellular microenvironments. [PJS acknowledges the
contributions of Prof. Rachel Errington (Cardiff University);
Prof. Stephanie McKeown (University of Ulster) and Robert
Falconer (Bradford University)].
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